Related Experiment Video
Updated: Apr 29, 2026
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
Published on: May 6, 2019
Induction of Bcl-xL-specific cytotoxic T lymphocytes in mice
H L Larsen1, M H Andersen, H H Wandall
1Department of International Health, Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Abstract:
The induction of active immunity against tumour-associated antigens to prevent relapse of cancer is a promising approach but has so far shown only low efficacy. This low efficacy may in part be due to clonal escape of tumour cell variants by the downregulation of antigen expression or inflammation-induced dedifferentiation. Identification of novel tumour-associated antigens that at the same time are essential for continued tumour cell survival is thus critical for the development of active cancer vaccinations. At the same time, identification of novel endogenous murine tumour antigens will help improve preclinical development of cancer immunotherapy. The anti-apoptotic protein Bcl-xL has been suggested to be such an essential tumour antigen, but the lack of well-defined murine epitopes have delayed preclinical studies of Bcl-xL-targeting cancer vaccines. Here, we report the identification of two novel murine tumour-associated epitopes TAYQSFEQV and AFFSFGGAL derived from mouse Bcl-xL. Dendritic cell (DC)-based vaccination induced CD8(+) T cells capable of producing IFN-γ upon restimulation with these epitopes. Thus, our data may benefit the design of future immunotherapy strategies by providing a preclinical model for cancer vaccination with an endogenous tumour antigen that can be combined with other cancer treatments.
Insights
Researchers identified novel tumor antigens from Bcl-xL to improve cancer vaccines. This approach enhances the development of effective cancer immunotherapies by targeting essential tumor survival proteins.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Active immunotherapy against tumor-associated antigens shows promise for preventing cancer relapse but suffers from low efficacy.
- Tumor cell variants can escape immune detection by downregulating antigen expression or dedifferentiation.
- Identifying essential tumor antigens is crucial for developing effective cancer vaccines.
Purpose of the Study:
- To identify novel murine tumor-associated epitopes from the anti-apoptotic protein Bcl-xL.
- To investigate the potential of these epitopes in preclinical cancer vaccination models.
- To improve the development of cancer immunotherapy strategies.
Main Methods:
- Identification of two novel murine tumor-associated epitopes (TAYQSFEQV and AFFSFGGAL) derived from mouse Bcl-xL.
- Dendritic cell (DC)-based vaccination in a preclinical model.
- Assessment of CD8(+) T cell response, including IFN-γ production upon epitope restimulation.
Main Results:
- Two novel Bcl-xL-derived murine tumor epitopes were identified.
- Dendritic cell vaccination successfully induced CD8(+) T cells.
- These T cells produced IFN-γ when restimulated with the identified epitopes, indicating an active immune response.
Conclusions:
- The identified Bcl-xL epitopes provide a promising target for cancer vaccination.
- This study offers a preclinical model for developing cancer vaccines targeting endogenous tumor antigens.
- These findings can inform the design of future immunotherapies, potentially combined with other cancer treatments.
